Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

According to the abstract, 35, participants were involved.

PubMed indexes the participants as adults.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Prednisone or prednisone placebo was stopped if Day-7 Lille score was >0.45.

The primary endpoint was overall survival at 90 days.

What Was Measured

The subject headings attached to it are Prednisone, Interleukin 1 Receptor Antagonist Protein, Zinc, Hepatitis, Alcoholic and Acute Kidney Injury.

The authors tagged it with the keywords Corticosteroids, IL1-inhibitor, alcoholic hepatitis, anakinra and survival.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 35, participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Journal of hepatology), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.